Syrosingopine sensitizes cancer cells to killing by metformin
暂无分享,去创建一个
T. Sharpe | H. Lane | D. Benjamin | M. Colombi | C. Moroni | C. Betz | S. Moes | L. Quagliata | S. K. Hindupur | M. El-Shemerly | A. Wodnar‐Filipowicz | Luigi Terracciano | Michael N. Hall | Min Lu | Don Benjamin | S. Hindupur
[1] P. Austin,et al. Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis , 2017, Clinical genitourinary cancer.
[2] T. Sharpe,et al. Syrosingopine sensitizes cancer cells to killing by metformin , 2016, Science Advances.
[3] S. Wild,et al. Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. , 2016, Lung cancer.
[4] P. Goodwin,et al. Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. , 2016, Cell metabolism.
[5] Sven Christian,et al. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? , 2016, Cell metabolism.
[6] L. Platanias,et al. Repurposing metformin for cancer treatment: current clinical studies , 2016, Oncotarget.
[7] J. Kos,et al. Gamma-enolase: a well-known tumour marker, with a less-known role in cancer , 2015, Radiology and oncology.
[8] M. V. Heiden,et al. Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.
[9] A. Zwinderman,et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2015, The Lancet. Oncology.
[10] B. Masquida,et al. A Moonlighting Human Protein Is Involved in Mitochondrial Import of tRNA , 2015, International journal of molecular sciences.
[11] V. Bae-Jump,et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer , 2014, Cancer medicine.
[12] J. Ioannidis,et al. Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial , 2014, Diabetes Care.
[13] M. Pollak,et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria , 2014, The Biochemical journal.
[14] Andrea Glasauer,et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis , 2014, eLife.
[15] I. Ben-Sahra,et al. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia. , 2014, Cancer letters.
[16] Thijs J. Hagenbeek,et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. , 2013, Cancer letters.
[17] J. Kos,et al. C-Terminal Peptide of γ-Enolase Impairs Amyloid-β-Induced Apoptosis Through p75NTR Signaling , 2013, NeuroMolecular Medicine.
[18] D. Braun,et al. Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. , 2013, Methods.
[19] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[20] Á. Díaz-Ramos,et al. α-Enolase, a Multifunctional Protein: Its Role on Pathophysiological Situations , 2012, Journal of biomedicine & biotechnology.
[21] M. Pollak. Investigating metformin for cancer prevention and treatment: the end of the beginning. , 2012, Cancer discovery.
[22] P. Goodwin,et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study , 2012, Breast Cancer Research and Treatment.
[23] R. DePinho,et al. In vitro enzymatic activity assay for ENOLASE in mammalian cells in culture , 2012 .
[24] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[25] A. Farmer,et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials , 2012, Diabetologia.
[26] A. Khurana,et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells , 2012, Cell cycle.
[27] J. Joseph,et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. , 2012, Cancer research.
[28] J. Kos,et al. γ-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways. , 2012, The Biochemical journal.
[29] Tetsuro Tsujimoto,et al. Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis , 2012, PloS one.
[30] P. Goodwin,et al. Understanding the benefit of metformin use in cancer treatment , 2011, BMC medicine.
[31] M. Capello,et al. α‐enolase: a promising therapeutic and diagnostic tumor target , 2011, The FEBS journal.
[32] C. Schaefer,et al. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction , 2011, Oncogene.
[33] J. Kos,et al. Gamma-1-Syntrophin Mediates Trafficking of Gamma-Enolase towards the Plasma Membrane and Enhances Its Neurotrophic Activity , 2011, Neurosignals.
[34] Massimiliano Cazzaniga,et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis , 2010, Cancer Prevention Research.
[35] P. Home,et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials , 2010, Diabetologia.
[36] Jing Chen,et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.
[37] W. Mikulits,et al. Hepatospheres: Three dimensional cell cultures resemble physiological conditions of the liver. , 2010, World journal of hepatology.
[38] J. Pelletier,et al. Target identification using drug affinity responsive target stability (DARTS) , 2009, Proceedings of the National Academy of Sciences.
[39] Funda Meric-Bernstam,et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Donnan,et al. New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.
[41] Nahum Sonenberg,et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.
[42] I. Popovich,et al. Metformin Decelerates Aging and Development of Mammary Tumors in HER-2/neu Transgenic Mice , 2005, Bulletin of Experimental Biology and Medicine.
[43] Dario R Alessi,et al. Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.
[44] M. Owen,et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.
[45] A. Subramanian,et al. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. , 2000, The Journal of biological chemistry.
[46] M. Rigoulet,et al. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.
[47] M. Murphy,et al. Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA. , 1999, European journal of biochemistry.
[48] C. Godinot,et al. Functional F1-ATPase Essential in Maintaining Growth and Membrane Potential of Human Mitochondrial DNA-depleted ρ° Cells* , 1998, The Journal of Biological Chemistry.
[49] J. Henry,et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. , 1994, The Journal of experimental biology.
[50] Y. Mizuno,et al. Synthetic peptide corresponding to 30 amino acids of the C-terminal of neuron-specific enolase promotes survival of neocortical neurons in culture. , 1994, Biochemical and biophysical research communications.
[51] R. Edwards,et al. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. , 1993, The Journal of biological chemistry.
[52] Jordi Félez,et al. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.
[53] M. King,et al. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.
[54] D. Scherman,et al. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. , 1989, Biochemistry.
[55] T. Olofsson,et al. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells. , 1984, Cancer research.
[56] J. Polak,et al. NEURON-SPECIFIC ENOLASE IS PRODUCED BY NEUROENDOCRINE TUMOURS , 1981, The Lancet.
[57] Y. Kohno,et al. Selective depleting effect of syrosingopine on braib catecholamine levels with relation to morphine analgesia in the rat , 1976, Pharmacology Biochemistry and Behavior.
[58] C. Bartels. Syrosingopine: a new rauwolfia preparation. , 1959, The New England journal of medicine.
[59] B. Calesnick,et al. REDUCED SEDATIVE EFFECT OF A NEWLY SYNTHESIZED RESERPINE DERIVATIVE (SYROSINGOPINE): CLINICAL APPRAISAL IN PRIMARY HYPERTENSION , 1959, Journal of the American Geriatrics Society.
[60] G. Chang,et al. Surface a -Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target , 2013 .
[61] C. Chong,et al. Mysterious metformin. , 2009, The oncologist.